No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.
The results of this cohort study suggest that individuals with type 2 diabetes who initiated treatment with empagliflozin or dapagliflozin had comparable long-term kidney outcomes. These ...
Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies ...